Biocept, Inc. (NASDAQ: BIOC)
Biocept is having a great day in the market today after announcing the launch of their c-MET Biomarker. So below, we’ll discuss what the c-MET Biomarker is, what we’ve seen in the market as a result of the announcement, and what we can expect to see moving forward. So, let’s get right to it…
Biocept’s c-MET Biomarker
Biocept’s c-MET signaling pathway is used in liquid biopsies and has the potential to help physicians identify whether or not a patient will be receptive to certain non-small-cell lung cancer treatments. The signaling pathway has proven to be dysfunctional in a wide variety of cancers. As a result, it stimulates cell growth, invasion and metastasis. As a result, Biocept is working to create new cancer therapies, currently in the development phase using the c-MET technology. Preliminary studies show that the c-MET inhibitor showed promise in treating c-MET-amplified GI cancers. Veena Singh, M.D., SVP and Senior Medical Director for BIOC had the following to say…
“It has been demonstrated that high levels of c-MET correlate with poor prognosis in several tumor types, including breast, ovarian, gastric, and lung cancer among others….Now the excitement around c-MET is focused on its potential as a biomarker that will be a companion diagnostic for targeted therapies in gastric and lung cancer.”
How The Market Reacted To The News
As mentioned above, Biocept is having a great day in the market today. The simple fact is that investors see value in c-MET; and why shouldn’t they? Biocept has proven that c-MET inhibitors can be effective in treating one of the world’s most devastating ailments. With that said, BIOC is currently (10:54) trading at $3.08 per share after a gain of 11.19% so far today.
What We Can Expect From Biocept Moving Forward
Moving forward, I’m expecting to see great things from BIOC in both the short term and long term outlook. In the short term, investor excitement following the c-MET biomarker announcement should keep this thing moving up. In the long term, the company continues to innovate and find ways to diagnose and treat some of the most invasive forms of cancer. All in all, this has long term profit potential. While we will most likely see the general small-cap biotech volatility; I think we’re in for big gains in the long run!
What Do You Think?
Where do you think BIOC is headed and why? Let us know in the comments below!